Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression (PREVAIL3)
2013年10月31日 更新者:Sunovion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression.
This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective among patients with bipolar I depression.
研究概览
研究类型
介入性
注册 (实际的)
356
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Dnipropetrovsk、乌克兰、49005
- Dnipropetrovsk Regional Clinical Hospital named Mechnikov
-
Dnipropetrovsk、乌克兰、49115
- Com Inst Knipropetrovsk Reg Cl Psych Hospital DSMA
-
Kharkov、乌克兰
- St. In. Inst of Neurol, Psych, and Narcol of the AMSU
-
Kyiv、乌克兰、02660
- Kyiv City Psychoneurological Hospital #2
-
Lviv、乌克兰、79021
- Lviv Regional Clinical Psychiatric Hospital
-
Ternopil、乌克兰、46020
- Ternopil Regional Municipal Dispensary, Narcology Dept.
-
Zaporizhzhya、乌克兰、69032
- Zapor. Reg. CI Hospital, Zaporizhzhia SMU
-
-
Vil Stepanivka
-
Kherson、Vil Stepanivka、乌克兰、73488
- Kherson Regional Psychiatric Hospital
-
-
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6L 6W6
- Clinical Research Group Edmonton Inc
-
-
British Columbia
-
Kelowna、British Columbia、加拿大、V1Y 1Z9
- Okanagan Clinical Trials
-
-
Quebec
-
Gatineau、Quebec、加拿大、J9A 1K7
- Pierre-Janet Hospital
-
Montreal、Quebec、加拿大、H1N 3M5
- Hopital Louis-H Lafontaine
-
-
-
-
Andh Prad
-
Vishakhapatnam、Andh Prad、印度、530002
- Brain Mind Behavior Neuroscience Research Institute
-
-
Aurangabad, Maharashtra
-
Kanchanpalli、Aurangabad, Maharashtra、印度
- Shanti Nursing Home
-
-
Gujarat
-
Vadodara、Gujarat、印度、390001
- SBKS Medical College and Hospital, Brij Psychiatry Hospital
-
-
Karna
-
Bangalore、Karna、印度、560027
- Abhaya Hospital Psychiatry
-
Mangalore、Karna、印度、575018
- K.S. Hegde Medical Academy
-
-
Mahara
-
Pune、Mahara、印度、411 030
- Poona Hospital & Research Center
-
Wardha、Mahara、印度、442102
- Mahatma Ghandi Institute of Medical Sciences
-
-
Rajasthan
-
Jaipur、Rajasthan、印度、302017
- Mental Health Care & Research
-
Jaipur、Rajasthan、印度、302021
- R.K. Yadav Memorial Mental Health & De-Addiction Hospital
-
-
Uttar Prad
-
Kanpur、Uttar Prad、印度、208005
- Mahendru Psychiatric Center
-
-
Utter Prad
-
Lucknow、Utter Prad、印度、226003
- Chatrapati Shau Maharaj Medical University
-
-
-
-
-
Barranquilla、哥伦比亚
- Centro de Investigaciones y Proyectos en Neurociencias CIPNA
-
Bogota、哥伦比亚、103
- Centro de Investigación y Atención para la Salud Mental
-
Bogota、哥伦比亚
- CISNE - UIC Campo Abierto
-
Cali、哥伦比亚
- Hospital Mental de Antioquia
-
-
-
-
-
Brno-mesto、捷克共和国、602 00
- Psychiatricka ambulance
-
Olomouc、捷克共和国、711 11
- Vojenska nemocnice Olomouc
-
Praha、捷克共和国、10 100 00
- CLINTRIAL, s.r.o.
-
Praha、捷克共和国、158 00
- Psychiatry Trial s.r.o.
-
-
-
-
-
Bardejov、斯洛伐克、085 01
- Centrum zdravia R. B. K. s.r.o.
-
Bojnice、斯洛伐克、97201
- Bojniciach
-
Bratislava、斯洛伐克、82007
- Psychiatricka Ambulancia Mentum S.R.O.
-
Bratislava、斯洛伐克、82606
- FNsP Bratislava, Nemocnica Ruzinov
-
Liptovsky Mikulas、斯洛伐克、03123
- Nemocnica s poliklinikou Liptovsky Milulas
-
Rimavska Sobota、斯洛伐克、97901
- PsychoLine s.r.o.
-
Roznava、斯洛伐克、048 01
- Nemocnica s poliklikou Sv. Barbory
-
Trencin、斯洛伐克、91101
- Pro mente sana
-
-
-
-
-
Hachioji-shi、日本、192 0153, 13
- Ongata Hospital
-
Ichikawa、日本、272 8516 12
- Kohnodai Hospital, National Center for Global Health & Medicine
-
Kanzaki-gun、日本、842 0192 41
- National Hospital Organization Hizen Psychiatric Center
-
Kodaira-shi、日本、187 8551 13
- National Center of Neurology & Psychiatry
-
Sakai-shi、日本、590 0018, 27
- Asakayama General Hospital
-
Takatsuki、日本、569-1041
- Osaka Institute of Clinical Psychiatry Shin-Abuyama Hospital
-
-
-
-
-
Lima、秘鲁、01
- Hospital Nacional Arzobispo Loayza
-
Lima、秘鲁、27
- Hospital Nacional Hipolito Unanue
-
Lima、秘鲁、41
- Clinica Vesalio
-
-
-
-
-
Kaunas、立陶宛、50185
- Neuromeda JSC
-
Kaunas、立陶宛、53136
- Ziegzdriai Mental Hospital, Public Institution
-
Silute、立陶宛、99142
- Silutes Mental Health & Psychtherapy Center, JSC
-
Vilnius、立陶宛、07156
- Seskines Outpatient Clinic, Public Institution
-
Vilnius、立陶宛、09112
- Zirmunai Mental Health Center, Public Institution
-
-
-
-
California
-
Costa Mesa、California、美国、92647
- Clinical Innovations, Inc.
-
Riverside、California、美国、92506
- Clinical Innovations Inc.
-
San Diego、California、美国、92123
- Sharp Mesa Vista Hospital
-
San Diego、California、美国、92123
- Artemis Institute for Clinical Research
-
Santa Ana、California、美国、92705
- Clinical Innovations Inc.
-
Torrance、California、美国、90502
- Collaborative Neuroscience Network
-
-
Colorado
-
Highlands Ranch、Colorado、美国、80130
- Colorado Clinical Trials Inc.
-
-
Florida
-
Kissimmee、Florida、美国、34741
- Accurate Clinical Trials
-
Orlando、Florida、美国、32806
- Clinical Neuroscience Solutions Inc.
-
-
Georgia
-
Roswell、Georgia、美国、30076
- Northwest Behavioral Research Center
-
Smyrna、Georgia、美国、30080
- Institute for Behavioral Medicine LLC
-
-
Mississippi
-
Flowood、Mississippi、美国、39232
- Precise Research Centers
-
-
New York
-
New York、New York、美国、10003
- Village Clinical Research Inc.
-
New York、New York、美国、10023
- Medical & Behavioral Health Research
-
-
North Carolina
-
Raleigh、North Carolina、美国、27607
- Zarzar Psychiatric Associates, Pllc
-
-
Oregon
-
Portland、Oregon、美国、97210
- Summit Research Network (Oregon) Inc.
-
-
Pennsylvania
-
Allentown、Pennsylvania、美国、18103
- LeHigh Valley Hospital
-
-
Tennessee
-
Memphis、Tennessee、美国、38119
- Clinical Neuroscience Solutions, Inc.
-
-
Texas
-
Dallas、Texas、美国、75231
- FutureSearch Clinical Trials, LP
-
Dallas、Texas、美国、75243
- Pillar Clinical Research
-
Houston、Texas、美国、77090
- Red Oak Psychiatry Associates, PA
-
-
Washington
-
Seattle、Washington、美国、98104
- Summit Research Network (Seattle) Llc
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Provide written informed consent and is 18 to 75 years of age inclusive.
- Meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.
- Has a lifetime history of at least one bipolar manic or mixed manic episode.
- Currently being treated with lithium or divalproex or willing to begin treatment with lithium or divalproex.
- Not pregnant or nursing and is not planning pregnancy within the projected duration of the study.
- Females of reproductive potential agree to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after
- Good physical health on the basis of medical history, physical examination, and laboratory screening.
Exclusion Criteria:
- Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
- Any chronic organic disease of the CNS (other than Bipolar I Disorder).
- Hospitalization for a manic or mixed episode within the past two months.
- Used investigational compound within past 6 months.
- Clinically significant history of alcohol or substance abuse within the past 3 months or alcohol or substance dependence within the past 12 months.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
Equivalent to Lurasidone dosing
|
|
实验性的:Lurasidone 20-120 mg flexible dose
|
Tablets 20-120 mg, PM dosing,daily for 6 weeks
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)
大体时间:Baseline to week 6
|
MADRS total score ranges from a minimum of 0 to a maximum of 60.
Lower values represent a better score, higher values represent a worse score.
Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
|
Baseline to week 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
大体时间:Baseline to week 6
|
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score.
Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
|
Baseline to week 6
|
|
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score
大体时间:Baseline to week 6
|
SDS total score ranges from a minimum of 0 to a maximum of 30.
Lower values represent a better score, higher values represent a worse score.
Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
|
Baseline to week 6
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2010年11月1日
初级完成 (实际的)
2012年8月1日
研究完成 (实际的)
2012年8月1日
研究注册日期
首次提交
2011年1月25日
首先提交符合 QC 标准的
2011年1月25日
首次发布 (估计)
2011年1月27日
研究记录更新
最后更新发布 (估计)
2013年11月26日
上次提交的符合 QC 标准的更新
2013年10月31日
最后验证
2013年10月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.